ABSTRACT
INTRODUCTION Botulinum toxin type A (BTX-A) was introduced for cosmetic use in the early 1990s, and has since become extremely popular with patients seeking safe, effective, and minimally invasive treatment to address the appearance of premature aging caused by facial lines. The outstanding results yielded by BTX-A treatment in tandem with the simplicity of the treatment process itself have combined to place BTX-A injections among the most commonly performed cosmetic procedures today. The exponential growth of this modality shows no signs of abating.
